Iovance Biotherapeutics, Inc. IOVA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s return on equity?
- Iovance Biotherapeutics, Inc. (IOVA) reported return on equity of -47.5% in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s return on equity changed year-over-year?
- Iovance Biotherapeutics, Inc.'s return on equity increased by 8.4% year-over-year, from -51.8% to -47.5%.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s return on equity?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s return on equity has grown at a 0.4% compound annual growth rate (CAGR), from -54.3% to -55.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.